­The last few years have seen an explosion of impressive clinical results in the field of immunotherapy, representing some of the most promising advancements in disease treatment. One immuno-oncology platform that has demonstrated incredible therapeutic potential is the bispecific T cell engager (BiTE) technology. This technology harnesses a patient’s...

Glioblastoma (GBM) is a common and highly aggressive brain tumor that affects over 11,000 patients every year in the US alone. Standard of care includes surgical resection, radiation therapy, and chemotherapy. Even with these aggressive treatments, outcomes remain poor, with a 5 year survival rate of approximately 5%. Many small molecule chemotherapeutics...